Use of Alternative Dosing Efgartigimod for the Treatment of Myasthenia Gravis (P1-11.020)

To report cases where alternative dosing of efgartigimod in generalized myasthenia gravis was more effective than the traditional dosing pattern.

Authors

Institutions

Publication Details

Journal
Neurology
Published
2025-04-07
DOI
https://doi.org/10.1212/wnl.0000000000212227
Primary Topic
Myasthenia Gravis and Thymoma
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Use of Alternative Dosing Efgartigimod for the Treatment of Myasthenia Gravis (P1-11.020)

Komal Sawlani, Bashar Katirji, David Preston, John Sturgis
Neurology
Myasthenia Gravis and Thymoma
article

Use of Alternative Dosing Efgartigimod for the Treatment of Myasthenia Gravis (P1-11.020)

Komal Sawlani, Bashar Katirji, David Preston, John Sturgis
article en

Abstract

To report cases where alternative dosing of efgartigimod in generalized myasthenia gravis was more effective than the traditional dosing pattern.

NeurologyVol. 104(7_Supplement_1)
University Hospitals of Cleveland (US)
Zero hunger
Openalex Percentile: Top 88%
Myasthenia Gravis and Thymoma
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Use of Alternative Dosing Efgartigimod for the Treatment of Myasthenia Gravis (P1-11.020) — Komal Sawlani, Bashar Katirji, et al. · Neurology (2025) | TGRS Research Map | TGRS